By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies
Global representatives of the diagnostics and pharmaceutical industries issued a joint declaration at the World Economic Forum in Davos, Switzerland calling on governments to take action, along with private companies, to support investment in the development of products to combat antimicrobial resistance…
Read more...
By Kelly A. Briganti, Editorial Director, G2 Intelligence
As federal agencies including the FDA and CMS encourage interoperability and increased sharing of patient information to inform and improve value of care and decrease costs, the risks inherent in that connectivity are also a central concern. New draft FDA guidance highlights that a "growing number of medical devices are designed to be networked to facilitate…
Read more...
By Ron Shinkman, Editor, Laboratory Industry Report
LabCorp has agreed to carry Interpace Diagnostics' microRNA thyroid assay on its test menu. The test, known as ThyraMir, is intended to provide more clarity for how patients should proceed regarding nodules on their thyroid. Up to 7 percent of the U.S. population have nodules on their thyroids, but less than 20 percent are…
Read more...
By Stephanie Murg, Managing Director, G2 Intelligence
A new biomarker shows promise as a way to determine which colon cancer patients stand to benefit from chemotherapy. Researchers zeroed in on the prognostic potential of the transcription factor CDX2 (caudal-type homeobox transcription factor 2). Lack of CDX2 expression identified a subgroup of patients with…
Read more...
|
